Payment overview · 2025
General Payments
$2,384.93
117 reported records · 29 companies
Healthcare provider profile · identity verified
Gurpreet K Narula, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSBORO, TN · NPI 1619908597
Verified facts
What the public records show
CMS Open Payments records show Gurpreet K Narula, M.D. received $2,384.93 in general payments during 2025 across 117 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Ozempic, Rexulti, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Auvelity by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $444.45 | 18.6% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $259.39 | 10.9% | 16 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $178.28 | 7.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $168.78 | 7.1% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $154.40 | 6.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $130.28 | 5.5% | 8 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $121.97 | 5.1% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.92 | 3.6% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.16 | 3.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $78.33 | 3.3% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $77.41 | 3.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.56 | 3.1% | 8 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $64.06 | 2.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.53 | 2.6% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $59.29 | 2.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.28 | 2.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.45 | 2.3% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $33.46 | 1.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.22 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.50 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.80 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.22 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.28 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.15 | 0.7% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $16.88 | 0.7% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $16.49 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.46 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.51 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,342.43 | 116 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $379.20 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $323.18 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $299.23 | 3 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $290.18 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $282.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $259.39 | 16 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $178.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $130.28 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $121.97 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.92 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $78.33 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $77.41 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $73.56 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $59.99 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $59.29 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $55.45 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 150 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 123 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 125 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 125 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
59 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
59 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 47 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
123 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
123 | 40 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
125 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 651 | 126 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 587 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 170 |
| Alprazolam | Alprazolam | 489 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 168 |
| Lisinopril | Lisinopril | 407 | 130 |
| Omeprazole | Omeprazole | 382 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 276 | 41 |
| Furosemide | Furosemide | 273 | 95 |
| Metformin Hcl | Metformin Hcl | 261 | 80 |
| Promethazine Hcl | Promethazine Hcl | 239 | 54 |
| Prednisone | Prednisone | 236 | 128 |
| Cephalexin | Cephalexin | 235 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 85 |
| Clonazepam | Clonazepam | 215 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 201 | 38 |
| Lorazepam | Lorazepam | 196 | 51 |
| Potassium Chloride | Potassium Chloride | 196 | 71 |
| Ibuprofen | Ibuprofen | 194 | 65 |
| Levofloxacin | Levofloxacin | 191 | 146 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 72 |
| Meloxicam | Meloxicam | 155 | 75 |
| Farxiga | Dapagliflozin Propanediol | 150 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 149 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 45 |
| Pregabalin | Pregabalin | 129 | 25 |
| Eliquis | Apixaban | 126 | 37 |
| Trazodone Hcl | Trazodone Hcl | 125 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 47 |
| Trintellix | Vortioxetine Hydrobromide | 125 | 40 |
| Rexulti | Brexpiprazole | 123 | 40 |
| Buspirone Hcl | Buspirone Hcl | 122 | 42 |
| Azithromycin | Azithromycin | 104 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | suppressed |
| Cefdinir | Cefdinir | 94 | 76 |
| Alendronate Sodium | Alendronate Sodium | 93 | 29 |
| Mounjaro | Tirzepatide | 93 | 16 |
| Sulindac | Sulindac | 91 | 32 |
| Ozempic | Semaglutide | 88 | 25 |
| Famotidine | Famotidine | 82 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 38 |
| Losartan Potassium | Losartan Potassium | 80 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 26 |
| Alcohol Pads | Alcohol Antiseptic Pads | 75 | 20 |
| Methocarbamol | Methocarbamol | 74 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 31 |
| Methylprednisolone | Methylprednisolone | 71 | 56 |
| Mirtazapine | Mirtazapine | 71 | 25 |
| Rybelsus | Semaglutide | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 25 |
| Tramadol Hcl | Tramadol Hcl | 68 | 28 |
| Fluconazole | Fluconazole | 67 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 30 |
| Carvedilol | Carvedilol | 65 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 56 |
| Simvastatin | Simvastatin | 62 | 18 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 59 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 23 |
| Jardiance | Empagliflozin | 59 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 19 |
| Vraylar | Cariprazine Hcl | 59 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 42 |
| Sertraline Hcl | Sertraline Hcl | 56 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 19 |
| Nystatin | Nystatin | 54 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 31 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 13 |
| Fenofibrate | Fenofibrate | 48 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 28 |
| Montelukast Sodium | Montelukast Sodium | 47 | 22 |
| Mupirocin | Mupirocin | 47 | 33 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Glimepiride | Glimepiride | 42 | 13 |
| Spironolactone | Spironolactone | 41 | 21 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Linzess | Linaclotide | 39 | 16 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Gemtesa | Vibegron | 38 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 38 | 16 |
| Topiramate | Topiramate | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 15 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Livalo | Pitavastatin Calcium | 36 | suppressed |
| Valsartan | Valsartan | 36 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 17 |
| Atenolol | Atenolol | 33 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | 11 |
| Doxepin Hcl | Doxepin Hcl | 33 | 16 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 14 |
| Diclofenac Sodium Er | Diclofenac Sodium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Nabumetone | Nabumetone | 31 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 26 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 24 | 17 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | 11 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Cefaclor | Cefaclor | 20 | 11 |
| Flucytosine | Flucytosine | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Ibu | Ibuprofen | 18 | 11 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Easy Comfort Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,384.93 · 117 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AREXVY, BREZTRI, BodyGuardian, CAPLYTA, CeQur Simplicity, Dexcom G6 Transmitter, ELIQUIS, ENHERTU, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GLYCATE, GVOKE HYPOPEN, JOURNAVX, Kerendia, Korlym, MINIMED 780G, Ohtuvayre, Ozempic, QULIPTA, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REXULTI, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, TWIIST, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZENPEP, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error